The Gastrointestinal Stromal Tumor Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
What are the Historical Growth Trends in the Gastrointestinal Stromal Tumor Market?
The market for gastrointestinal stromal tumors has seen robust growth in recent years. The market valuation has risen from $1.28 billion in 2024 to an estimated $1.37 billion in 2025. This represents a compound annual growth rate (CAGR) of 7.2%.
What are the 2025 Market Projections: Forecasted Size & Growth Rate for the Gastrointestinal Stromal Tumor Industry?
The global gastrointestinal stromal tumor market is projected to reach a size of $1.82 billion in 2029, experiencing a Compound Annual Growth Rate (CAGR) of 7.4%.
Download Your Free Sample of the 2025 Gastrointestinal Stromal Tumor Market Report and Uncover Key Trends Now!
What are the Key Growth Drivers Fueling the Gastrointestinal Stromal Tumor Market?
The key drivers in the gastrointestinal stromal tumor market are:
• Continued research and drug development for gastrointestinal stromal tumors
• Rise in patient-centric healthcare practices
• Integration of precision medicine in clinical practice
• Increased access to targeted therapies for patients.
Global Market Segmentation: Identifying Major Gastrointestinal Stromal Tumor Industry Segments
The gastrointestinal stromal tumor market covered in this report is segmented –
1) By Treatment Type: Chemotherapy, Targeted Therapy, Other Treatment Types
2) By Indication: Stomach, Small Intestine, Others Indications
3) By End-User: Hospitals, Clinics, Specialized Cancer Treatment Centers, Other End-Users
Pre-order the 2025 Gastrointestinal Stromal Tumor Global Market Report for Fast Delivery & Comprehensive Insights!
What are the Emerging Trends Shaping the Future of the Gastrointestinal Stromal Tumor Market?
The key trends in the gastrointestinal stromal tumor market are:
• Continued research, drug development and integration of precision medicine in clinical practice are expected to shape the future of the market.
• Increasing access to targeted therapies with expansion of genomic profiling capabilities is set to be a significant trend.
• Growing collaborations in R&D and advancements in diagnostic technologies will likely play substantial roles.
• Increased focus on early detection and diagnosis, as well as the exploration of combination therapies, will likely influence future market developments.
Who Are the Top Competitors & Leading Players in the Gastrointestinal Stromal Tumor Market?
Major companies in the gastrointestinal stromal tumor market are:
• Pfizer Inc.
• F. Hoffmann-La Roche AG
• Bayer AG
• Novartis AG
• Merck & Co. Inc.
• GlaxoSmithKline PLC
• Bristol-Myers Squibb Company
• Sanofi S.A.
• AstraZeneca PLC
• Eli Lilly and Company
• Daiichi Sankyo Co. Ltd.
• Eisai Co. Ltd.
• Sun Pharmaceutical Industries Limited
• Jiangsu Hengrui Medicine Co. Ltd.
• Exelixis Inc.
• NATCO Pharma Ltd.
• Blueprint Medicines Corporation
• Array BioPharma Inc.
• Deciphera Pharmaceuticals Inc.
• Ono Pharmaceutical Co. Ltd.
• Boston Biomedical Inc.
• DNAtrix Inc.
• Advenchen Laboratories LLC
• Arog Pharmaceuticals Inc.
• AB Sciences S.A.
Regional Dominance: Which Area Leads the Global Gastrointestinal Stromal Tumor Market?
North America was the largest region in the gastrointestinal stromal tumor market in 2024
